Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06323928 · ClinicalTrials.gov registry record · Phase 2
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
A Phase 2 study of Migraine, sponsored by H. Lundbeck A/S.
- Active
- Registry status
- Phase 2
- Development phase
- 874
- Enrollment target
- 20
- Study locations
NCT06323928: Active Phase 2 study of Migraine, sponsored by H. Lundbeck A/S.
NCT06323928 is a Phase 2 study of Migraine that is active but no longer recruiting, run by H. Lundbeck A/S. The registered enrollment target is 874 participants, above the 350-participant average among 102 other Migraine trials with a reported enrollment target (150% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06323928, a Phase 2 study of Migraine, is active but no longer recruiting, sponsored by H. Lundbeck A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 874 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lu AG09222
Study Locations (20)
Florida
- K2 Medical Research - Winter Garden - Clermont
- Clinical Neuroscience Solutions, Inc. - Jacksonville
- K2 Medical Research, LLC - Maitland - Maitland
- Aqualane Clinical Research - Naples
- K2 Medical Research Tampa LLC - Tampa
- Premiere Research Institute Palm Beach - West Palm Beach
California
- Profound Research - Neurology Center of Southern California - Carlsbad
- Neurology Center of North Orange County - Fullerton
- CenExel CNS - Los Alamitos
- ASCLEPES Research Centers - Sherman Oaks
North Carolina
- Accellacare of Cary - Cary Medical Group - Cary
- Headache Wellness Center - Greensboro
- Raleigh Medical Group - Raleigh
Missouri
- Clinical Research Professionals - Chesterfield
- Healthcare Research Network - Hazelwood
New York
- Dent Neurosciences Research Center, Inc. - Amherst
- North Suffolk Neurology, PC. - Port Jefferson Station
Alabama
- Accel Research Sites Network - Neurology and Neurodiagnostic of Alabama - Hoover
Connecticut
- Ki Health Partners LLC DBA New England Institute for Clinical Research - Stamford
Iowa
- Accellacare and McFarland Clinic - Ames
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 874 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 2 |
What the registry record for NCT06323928 still lists
NCT06323928 is an interventional study that assigns participants to a tested intervention. The registered 874 participants enrollment target is mid-sized for trials with a published cap, above the 350-participant average among 102 other Migraine trials with a reported enrollment target (150% higher).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06323928 names 20 study sites across 8 states, led by Florida, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06323928 about?
NCT06323928 is a clinical study titled "A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments". The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.
What is the current status of trial NCT06323928?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 874 participants. The study started on 2024-04-01. Estimated completion is 2026-04-30.
What conditions does trial NCT06323928 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT06323928?
The interventions under investigation include: Placebo (DRUG), Lu AG09222 (DRUG).
Who is sponsoring clinical trial NCT06323928?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06323928 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06323928's enrollment target sits among peer trials
874 12th of 102 higher than 91 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
RECRUITING · Phase 2
-
Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
RECRUITING · Phase 2
-
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
COMPLETED · Phase 2
-
CHOCOlate MeLatonin for AdolescenT MigrainE
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07076199 · 877 participants · Phase 3
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
- NCT06627647 · 878 participants · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
- NCT04097145 · 870 participants · NA
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
- NCT06822790 · 869 participants · Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI